Julian Späth

Julian Späth

Auto-generated profile, based on publicly available information

Julian Späth

Institute for Computational Systems Biology University of Hamburg Hamburg Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSSepideh Sadegh
Sepideh Sadegh
JMJulian Matschinske
Julian Matschinske
DBDavid B. Blumenthal
David B. Blumenthal
GGGihanna Galindez
Gihanna Galindez
TKTim Kacprowski
Tim Kacprowski
Jan BaumbachJan Baumbach
Jan Baumbach
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Various studies exist about the molecular mechanisms of viral infection. However, such information is spread across many publications and it is very time-consuming to integrate, and exploit. We develop CoVex, an interactive online platform for SARS-CoV-2 host interactome exploration and drug (target) identification. CoVex integrates virus-human protein interactions, human protein-protein interactions, and drug-target interactions. It allows visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drug candidates. Thus, CoVex is a resource to understand molecular mechanisms of pathogenicity and to prioritize candidate therapeutics. We investigate recent hypotheses on a systems biology level to explore mechanistic virus life cycle drivers, and to extract drug repurposing candidates. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms. It is available at https://exbio.wzw.tum.de/covex/.

14 January 2021 in Nature Computational Science
Verified
Journal Article
Closed access
PDF file
GGGihanna Galindez
Gihanna Galindez
JMJulian Matschinske
Julian Matschinske
TRTim Daniel Rose
Tim Daniel Rose
SSSepideh Sadegh
Sepideh Sadegh
MSMarisol Salgado-Albarrán
Marisol Salgado-Albarrán
Josch K. PaulingJosch K. Pauling
Josch K. Pauling

6 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
RNReza Nasirigerdeh
Reza Nasirigerdeh
RTReihaneh Torkzadehmahani
Reihaneh Torkzadehmahani
JMJulian Matschinske
Julian Matschinske
TFTobias Frisch
Tobias Frisch
MLMarkus List
Markus List
Jan BaumbachJan Baumbach
Jan Baumbach
Genome-wide association studies (GWAS) have been widely used to unravel connections between genetic variants and diseases. Larger sample sizes in GWAS can lead to discovering more associations and more accurate genetic predictors. However, sharing and combining distributed genomic data to increase the sample size is often challenging or even impossible due to privacy concerns and privacy protection laws such as the GDPR. While meta-analysis has been established as an effective approach to combine summary statistics of several GWAS, its accuracy can be attenuated in the presence of cross-study heterogeneity. Here, we present sPLINK ( safe PLINK ), a user-friendly tool, which performs federated GWAS on distributed datasets while preserving the privacy of data and the accuracy of the results. sPLINK neither exchanges raw data nor does it rely on summary statistics. Instead, it performs model training in a federated manner, communicating only model parameters between cohorts and a central server. We verify that the federated results from sPLINK are the same as those from aggregated analyses conducted with PLINK . We demonstrate that sPLINK is robust against heterogeneous data (phenotype and confounding factors) distributions across cohorts while existing meta-analysis tools considerably lose accuracy in such scenarios. We also show that sPLINK achieves practical runtime, in order of minutes or hours, and acceptable network bandwidth consumption for chi-square and linear/logistic regression tests. Federated analysis with sPLINK , thus, has the potential to replace meta-analysis as the gold standard for collaborative GWAS. The user-friendly, readily usable sPLINK tool is available at https://exbio.wzw.tum.de/splink .

29 March 2024 in JMIR AI
Verified
Journal Article
Open access
JSJulian Späth
Julian Späth
ZSZeno Sewald
Zeno Sewald
NPNiklas Probul
Niklas Probul
MBMagali Berland
Magali Berland
MAMathieu Almeida
Mathieu Almeida
Jan BaumbachJan Baumbach
Jan Baumbach
Background: Central collection of distributed medical patient data is problematic due to strict privacy regulations. Especially in clinical environments, such as clinical time-to-event studies, large sample sizes are critical but usually not available at a single institution. It has been shown recently that federated learning, combined with privacy-enhancing technologies, is an excellent and privacy-preserving alternative to data sharing. Objective: This study aims to develop and validate a privacy-preserving, federated survival support vector machine (SVM) and make it accessible for researchers to perform cross-institutional time-to-event analyses. Methods: We extended the survival SVM algorithm to be applicable in federated environments. We further implemented it as a FeatureCloud app, enabling it to run in the federated infrastructure provided by the FeatureCloud platform. Finally, we evaluated our algorithm on 3 benchmark data sets, a large sample size synthetic data set, and a real-world microbiome data set and compared the results to the corresponding central method. Results: Our federated survival SVM produces highly similar results to the centralized model on all data sets. The maximal difference between the model weights of the central model and the federated model was only 0.001, and the mean difference over all data sets was 0.0002. We further show that by including more data in the analysis through federated learning, predictions are more accurate even in the presence of site-dependent batch effects. Conclusions: The federated survival SVM extends the palette of federated time-to-event analysis methods by a robust machine learning approach. To our knowledge, the implemented FeatureCloud app is the first publicly available implementation of a federated survival SVM, is freely accessible for all kinds of researchers, and can be directly used within the FeatureCloud platform.

6 September 2022 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
JSJulian Späth
Julian Späth
JMJulian Matschinske
Julian Matschinske
FKFrederick K. Kamanu
Frederick K. Kamanu
SMSabina A. Murphy
Sabina A. Murphy
OZOlga Zolotareva
Olga Zolotareva
JBJan Baumbach
Jan Baumbach
Clinical time-to-event studies are dependent on large sample sizes, often not available at a single institution. However, this is countered by the fact that, particularly in the medical field, individual institutions are often legally unable to share their data, as medical data is subject to strong privacy protection due to its particular sensitivity. But the collection, and especially aggregation into centralized datasets, is also fraught with substantial legal risks and often outright unlawful. Existing solutions using federated learning have already demonstrated considerable potential as an alternative for central data collection. Unfortunately, current approaches are incomplete or not easily applicable in clinical studies owing to the complexity of federated infrastructures. This work presents privacy-aware and federated implementations of the most used time-to-event algorithms (survival curve, cumulative hazard rate, log-rank test, and Cox proportional hazards model) in clinical trials, based on a hybrid approach of federated learning, additive secret sharing, and differential privacy. On several benchmark datasets, we show that all algorithms produce highly similar, or in some cases, even identical results compared to traditional centralized time-to-event algorithms. Furthermore, we were able to reproduce the results of a previous clinical time-to-event study in various federated scenarios. All algorithms are accessible through the intuitive web-appPartea(https://partea.zbh.uni-hamburg.de), offering a graphical user interface for clinicians and non-computational researchers without programming knowledge.Partearemoves the high infrastructural hurdles derived from existing federated learning approaches and removes the complexity of execution. Therefore, it is an easy-to-use alternative to central data collection, reducing bureaucratic efforts but also the legal risks associated with the processing of personal data to a minimum.

20 November 2023 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
JSJulian Späth
Julian Späth
RWRui‐Sheng Wang
Rui‐Sheng Wang
MHMaeve Humphrey
Maeve Humphrey
Jan BaumbachJan Baumbach
Jan Baumbach
JLJoseph Loscalzo
Joseph Loscalzo
High drug development costs and the limited number of new annual drug approvals increase the need for innovative approaches for drug effect prediction. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), led to a global pandemic with high morbidity and mortality. Although effective preventive measures exist, there are few effective treatments for hospitalized patients with SARS-CoV-2 infection. Drug repurposing and drug effect prediction are promising strategies that could shorten development time and reduce costs compared with de novo drug discovery. In this work, we present a machine learning framework to integrate a variety of target network features and physicochemical properties of compounds, and analyze their influence on the therapeutic effects for SARS-CoV-2 infection and on host cell cytotoxic effects. Random forest models trained on compounds with known experimental effects on SARS-CoV-2 infection and subsequent feature importance analysis based on Shapley values provided insights into the determinants of drug efficacy and cytotoxicity, which can be incorporated into novel drug discovery approaches. Given the complexity of molecular mechanisms of drug action and limited sample sizes, our models achieve a reasonable mean area under the receiver operating characteristic curve (ROC-AUC) of 0.73 on an unseen validation set. To our knowledge, this is the first work to incorporate a combination of network and physicochemical features of compounds into a machine learning model to predict drug effects on SARS-CoV-2 infection. Our systems pharmacology-based machine learning framework can be used to classify other existing drugs for SARS-CoV-2 infection and can easily be adapted to drug effect prediction for future viral outbreaks.